Sanford Zweifach

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA.

Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.